Novo Nordisk A/S (BKK:NOVOB80)
Thailand · Delayed Price · Currency is THB | Market Cap | 6.46T -34.7% |
| Revenue (ttm) | 1.53T +6.4% |
| Net Income | 507.86B +1.4% |
| EPS | 114.18 +1.8% |
| Shares Out | n/a |
| PE Ratio | 12.71 |
| Forward PE | 13.39 |
| Dividend | 0.04 (2.81%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 13,190,740 |
| Average Volume | 4,674,480 |
| Open | 1.330 |
| Previous Close | n/a |
| Day's Range | 1.330 - 1.470 |
| 52-Week Range | 1.120 - 2.700 |
| Beta | n/a |
| RSI | 69.18 |
| Earnings Date | May 6, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 5 May 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of...
Novo Nordisk's weight-loss pill boom faces price war test
Novo Nordisk is seeing brisk early demand for its new weight-loss pill as competition with U.S. rival Eli Lilly intensifies. Investors now want proof that fast-rising prescriptions can offset a bruis...
Novo Nordisk's Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance
Novo Nordisk's Wegovy pill has created another boom in the GLP-1 drug market. Eli Lilly recently introduced its Foundayo pill for weight loss, three months after the launch of its rival's drug.
'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds
For the first time in 16 years, oncology is no longer the largest contributor to late-stage pipeline value, Deloitte has found. Pharma R&D returns for the world's top 20 pharma companies have improved...
Canada approves second generic version of Ozempic
The Canadian health regulator said on Friday that it had approved Canada-based Apotex's generic version of semaglutide, making it the second copycat version of Danish drugmaker Novo Nordisk...
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
The Food and Drug Administration proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's blockbuster obesity and diabetes medications from the list of drugs that outsourcing fa...
US FDA proposes excluding weight-loss drugs from compounding list
The U.S. Food and Drug Administration on Thursday proposed excluding active ingredients for Novo Nordisk and Eli Lilly's weight-loss drugs on the list of drugs outsourcing facilities can use for c...
WEBINAR INVITATION: Novo Resources Corp. Executive Co-Chairman to discuss the March Quarter Activities and Outlook
PERTH, Australia, April 30, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO & NVOO) (TSX: NVO) (OTCQX: NSRPF) is pleased to invite shareholders and investors to a Webinar...
Health Canada approves first generic version of Novo Nordisk's Ozempic
Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's blockbuster diabetes drug Ozempic made by Indian drugmaker Dr Reddy's Laboratories , its website s...
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achieved ...
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
Boehringer Ingelheim said on Tuesday its experimental obesity drug led to average weight loss of up to 16.6% in a late-stage trial, as the unlisted German drugmaker seeks to catch up with obesity dr...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 27 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
Novo Nordisk A/S (NYSE:NVO) shares are trading higher Friday after the company announced results of an oral semaglutide trial in children aged 10-17 years old with type 2 diabetes.
Novo Nordisk to Seek Approval for Pill to Treat Diabetes in Young Patients
A late-stage trial showed that oral semaglutide significantly reduced blood sugar in 10- to 17-year-olds.
Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study
Novo Nordisk's oral GLP-1 drug met the main goal of a late-stage study in children and adolescents aged 10 to 17 years with type 2 diabetes, the drugmaker said on Thursday.
Novo Nordisk's oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
PIONEER TEENS is the first clinical trial of an oral GLP-1 in children & adolescents 10–17 years with type 2 diabetes, addressing a significant unmet need
Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50
Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for GLP-1 medications for weight loss.
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390 prescriptions for its newly launched obesity pill in the U.S. for the week ended April 10.
Should You Forget CVS Health and Invest in a Purer Healthcare Play?
CVS Health has a far more diversified business than Novo Nordisk. Both approaches have perks and disadvantages.
Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds
Eli Lilly's GLP-1 drug tirzepatide yields greater weight loss on average than Novo Nordisk's semaglutide, but at a greater expense to muscles and connective tissues, according to a study published t...
Novo Nordisk weight-loss drug shows liver benefits in mouse study
GLP-1 drugs have direct beneficial effects on the liver, independent of their benefits for obesity, researchers studying the medicines in mice with fatty liver disease have found.
Novo Nordisk CEO: This is where science meets speed and scale
Maziar Mike Doustdar, CEO of Novo Nordisk, says AI partnership with OpenAI will speed drug discovery and delivery, boost accuracy and strengthen confidence in Wegovy despite rising competition.
Novo Nordisk's stock rallies after drugmaker reveals deal with OpenAI
Novo Nordisk is working with OpenAI on a broad deal that will use artificial intelligence to more quickly develop new medications as well as help train its workforce.
Novo Nordisk Stock Rises. An OpenAI Partnership Can Help It Find the Next Ozempic.
Novo's OpenAI partnership will help it discover new therapies bringing them to market faster.
Novo Nordisk taps OpenAI to boost AI in drug development
Novo Nordisk on Tuesday announced a partnership with OpenAI to deploy artificial intelligence across its business, spanning drug discovery, manufacturing and commercial operations, as the Danish drugm...